Published February 8, 2022
- CADTH recommends that Dojolvi should be reimbursed by public drug plans as a source of calories and fatty acids for the treatment of adult and pediatric patients with a long-chain fatty acid oxidation disorders (LC-FAOD) if certain conditions are met.
- Dojolvi should only be covered to treat patients with and without a confirmed LC-FAOD diagnosis if they present with acute life-threatening symptoms that are consistent with those of LC-FAOD. Dojolvi should only be covered in patients who need a different treatment than over-the-counter even-chain medium-chain triglyceride (MCT) oil.
- Dojolvi should only be reimbursed if prescribed by clinicians experienced in the management of LC-FAOD and if the price of Dojolvi is reduced. Reimbursement of Dojolvi should be renewed every 12 months if individual patient treatment goals are being met.